logo

For the Inventor, By the Inventor

Brighton, MA, United States of America

Hong Ren

This inventor holds 4 USPTO granted patents and 1 published patent application. Top assignee: Bluefin Biomedicine, Inc.. Active years: 2023-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Hong Ren. Retrieved from https://idiyas.com/inventor/hong-ren-4heg0tg1

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 4 

% Patents Active = 100.0

Average Co-Inventor Count = 6.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:

goldMedal4 out of 17 
 
Bluefin Biomedicine, Inc.
 patents

Years Active: 2023-2025

Loading Chart...
4 patents (USPTO):Explore Patents
1. 12491256 - ANTI-CUB DOMAIN-CONTAINING PROTEIN 1 (CDCP1) ANTIBODIES, ANTIBODY DRUG CONJUGATES, AND METHODS OF USE THEREOF (2025-12-09),
2. 12138314 - Anti-CUB domain-containing protein 1 (CDCP1) antibodies, antibody drug conjugates, and methods of use thereof (2024-11-12),
3. 12138313 - Anti-cub domain-containing protein 1 (CDCP1) antibodies, antibody drug conjugates, and methods of use thereof (2024-11-12),
4. 11702481 - Anti-cub domain-containing protein 1 (CDCP1) antibodies, antibody drug conjugates, and methods of use thereof (2023-07-18),

Title: Innovations of Hong Ren in Cancer Treatment

Introduction

Hong Ren is a notable inventor based in Brighton, MA, who has made significant contributions to the field of cancer treatment. With a total of three patents to his name, he has focused on developing innovative solutions that enhance the effectiveness of cancer therapies. His work is particularly relevant in the realm of antibody-based treatments.

Latest Patents

Hong Ren's latest patents include the development of anti-CUB domain-containing protein 1 (CDCP1) antibodies and antibody drug conjugates. These patents detail methods of use that relate to anti-cancer antibodies, providing new avenues for treatment, detection, and diagnosis of cancer. The focus on CDCP1 highlights the potential for targeted therapies that can improve patient outcomes.

Career Highlights

Ren is currently associated with Bluefin Biomedicine, Inc., where he continues to push the boundaries of cancer research. His work at the company emphasizes the importance of innovative approaches in the fight against cancer, showcasing his commitment to advancing medical science.

Collaborations

Some of his notable coworkers include Scott Michael Lonning and Nels Eric Pederson, who contribute to the collaborative environment that fosters innovation at Bluefin Biomedicine, Inc. Their combined expertise enhances the development of groundbreaking therapies.

Conclusion

Hong Ren's contributions to cancer treatment through his patents and work at Bluefin Biomedicine, Inc. exemplify the impact of innovation in medicine. His focus on antibody-based therapies positions him as a key figure in the ongoing battle against cancer.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…